Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xemchem reports high Nigerian demand for sickle cell drug
Xechem Nigeria, which received regulatory approval for Nicosan on July 3rd, 2006 from the National Agency for Food and Drug Administration and Control of Nigeria (NAFDAC), has been
Xechem Nigeria, which received regulatory approval for Nicosan on July 3rd, 2006 from the National Agency for Food and Drug Administration and Control of Nigeria (NAFDAC), has been
The collaboration will focus on inhibitors of poly (ADP-ribose) polymerase (PARP). PARP is a nuclear enzyme within cells that directs the repair of damaged DNA via the activation
The vaccine, which uses a proprietary adjuvant, enabled over 80% of subjects who received 3.8 micrograms of antigen to demonstrate a strong seroprotective immune response. According to the
Avalon will use its proprietary AvalonRx platform to discover new active compounds in screens against selected targets and target pathways. ChemDiv will provide Avalon access to its Discovery
As part of the collaboration, Sandoz will make an initial payment of $75 million to Momenta for the purchase of approximately 4.7 million shares at a price of
Through this agreement, Asuragen will have access to microRNAs identified by a group led by Rockefeller University researcher Dr Thomas Tuschl. The microRNAs have been found to have
Avelox was developed by Bayer and is marketed in the US by Schering-Plough. The drug, the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat
Oncaspar had previously been indicated for patients with acute lymphoblastic leukemia (ALL) who require L-asparaginase in their treatment, but developed hypersensitivity to the native forms. “We are pleased
Dosing was initiated in February 2006 and Critical Therapeutics expects to report preliminary results from this trial later this quarter. The company is developing zileuton IV initially for
In the trial the compound, atacicept (formerly referred to as TACI-Ig), demonstrated a favorable tolerability profile and indicated biological activity consistent with the mode of action. The primary